SCHEMBL5149921

SCHEMBL5149921

COC(=O)c1ccc(OCC2(C)CCCN2)c([N+](=O)[O-])c1

nearest known ligand 0.46

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 8/20 0.46
▸ HPGD P15428 3/20 0.46
▸ NPSR1 Q6W5P4 1/20 0.46
▸ VCAM1 P19320 1/20 0.44
▸ ESRRA P11474 1/20 0.44
▸ LMNA P02545 4/20 0.43
▸ SMN1; SMN2 Q16637 2/20 0.43
▸ RAB9A P51151 1/20 0.43
▸ G6PD P11413 1/20 0.42
▸ KMT2A Q03164 3/20 0.41
▸ ALOX12 P18054 1/20 0.41
▸ POLB P06746 1/20 0.41
▸ MEN1 O00255 2/20 0.41
▸ GAA P10253 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5151446 0.76 CHRNB4 (0.50) ALDH1A1HPGDNPSR1VCAM1ESRRA
SCHEMBL17512389 0.76 GAA (0.64) ALDH1A1HPGDNPSR1VCAM1LMNA
SCHEMBL11790540 0.74 ALDH1A1 (0.56) ALDH1A1HPGDNPSR1VCAM1LMNA
SCHEMBL5913915 0.74 ALDH1A1 (0.56) ALDH1A1HPGDNPSR1VCAM1LMNA
SCHEMBL12569892 0.74 ALDH1A1 (0.56) ALDH1A1HPGDNPSR1VCAM1LMNA
SCHEMBL532856 0.74 ALDH1A1 (0.56) ALDH1A1HPGDNPSR1VCAM1LMNA
SCHEMBL31750473 0.73 ALDH1A1 (0.53) ALDH1A1HPGDNPSR1VCAM1ESRRA
SCHEMBL3931073 0.73 ALDH1A1 (0.53) ALDH1A1HPGDNPSR1VCAM1ESRRA
SCHEMBL30445111 0.73 ALDH1A1 (0.65) ALDH1A1HPGDNPSR1VCAM1LMNA
SCHEMBL7566531 0.73 ALDH1A1 (0.65) ALDH1A1HPGDNPSR1VCAM1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070054909-A1 VLA-4 inhibitor compounds DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2007-03-08 — — US disclosed
US-7179819-B2 VLA-4 inhibitor compounds DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2007-02-20 — — US disclosed
EP-1189612-A4 VLA-4 INHIBITOR COMPOUNDS DAIICHI SEIYAKU CO (JP) 2005-02-16 — — EP disclosed
US-20040229858-A1 VLA-4 inhibitor compounds DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2004-11-18 — — US disclosed
US-6756378-B2 BENZYL -UREA, -THIOUREA, OR -GUANIDINE DERIVATIVES THAT INHIBIT THE BINDING OF LIGANDS TO ALPHA 4 BETA 1 INTEGRIN (VLA-4) PHARMACOPEIA DRUG DISCOVERY, INC. 2004-06-29 — — US disclosed
US-20030078249-A1 VLA-4 inhibitor compounds DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2003-04-24 — — US disclosed
EP-1189612-A1 VLA-4 INHIBITOR COMPOUNDS Daiichi Pharmaceutical Co., Ltd. (JP) 2002-03-27 — — EP disclosed
WO-2001000206-A1 VLA-4 INHIBITOR COMPOUNDS DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2001-01-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030078249-A1 VLA-4 inhibitor compounds VCAM1, ICAM1, ITGA4 ALDH1A1 146/4885HPGD 4160/4885NPSR1 2506/4885
US-20070054909-A1 VLA-4 inhibitor compounds VCAM1, ITGB4, ICAM1 ALDH1A1 120/4885HPGD 4172/4885NPSR1 2578/4885
US-20040229858-A1 VLA-4 inhibitor compounds VCAM1, ICAM1, ITGB4 ALDH1A1 135/4885HPGD 4207/4885NPSR1 2415/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback